Sugi Predict

Sugi Predict / Compounds / SCHEMBL756362

SCHEMBL756362

SCHEMBL756362

CN(C)[C@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.61
▸ ALDH1A1 P00352 1/20 0.61
▸ CYP1A2 P05177 1/20 0.55
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ ALPI P09923 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ PTGS1 P23219 1/20 0.52
▸ XIAP P98170 1/20 0.52
▸ SLC7A5 Q01650 1/20 0.52
▸ ADAMTS5 Q9UNA0 1/20 0.51
▸ HPGD P15428 1/20 0.50
▸ CPA1 P15085 2/20 0.48
▸ CPA3 P15088 2/20 0.48
▸ FOLH1 Q04609 1/20 0.48
▸ CPB1 P15086 1/20 0.48
▸ CPB2 Q96IY4 1/20 0.48
▸ NR4A2 P43354 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121727 1.00 MAPT (0.61) MAPTALDH1A1CYP1A2MEN1KMT2A
SCHEMBL121728 1.00 MAPT (0.61) MAPTALDH1A1CYP1A2MEN1KMT2A
Hydrochloric Acid SCHEMBL6475636 0.98 ALDH1A1 (0.64) MAPTALDH1A1CYP1A2MEN1KMT2A
Hydrochloric Acid SCHEMBL1082353 0.98 ALDH1A1 (0.64) MAPTALDH1A1CYP1A2MEN1KMT2A
Hydrochloric Acid SCHEMBL1082351 0.98 ALDH1A1 (0.64) MAPTALDH1A1CYP1A2MEN1KMT2A
Trifluoroacetic Acid SCHEMBL4920524 0.91 ALDH1A1 (0.54) MAPTALDH1A1CYP1A2MEN1KMT2A
SCHEMBL10197473 0.89 ALDH1A1 (0.68) MAPTALDH1A1ADAMTS5CPA1SRR
SCHEMBL8605469 0.86 ALDH1A1 (0.59) MAPTALDH1A1CYP1A2MEN1KMT2A
SCHEMBL8337022 0.86 CYP1A2 (0.53) MAPTALDH1A1CYP1A2MEN1KMT2A
SCHEMBL12341937 0.86 ALDH1A1 (0.59) MAPTALDH1A1CYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9504727-B2 Oral delivery of peptide pharmaceutical compositions ENTERIS BIOPHARMA, INC. (US) 2016-11-29 — — US claimed
US-20150125522-A1 ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS ENTERIS BIOPHARMA, INC. 2015-05-07 — — US claimed
US-8835377-B2 Oral delivery of peptide pharmaceutical compositions UGP THERAPEUTICS, INC. (US) 2014-09-16 — — US claimed
US-20120328666-A1 ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS UNIGENE LABORATORIES INC. (US) 2012-12-27 — — US claimed
CN-101243044-A Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions ASTRAZENECA AB (SE) 2008-08-13 — — CN claimed
CN-101228123-A Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia ASTRAZENECA AB (SE) 2008-07-23 — — CN claimed
CN-101065354-A Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity ASTRAZENECA AB (SE) 2007-10-31 — — CN claimed
EP-1755633-A1 ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS Unigene Laboratories, Inc. (US) 2007-02-28 — — EP claimed
WO-2006007332-A1 ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS UNIGENE LABORATORIES, INC. (US) 2006-01-19 — — WO claimed
US-20050282756-A1 Oral delivery of peptide pharmaceutical compositions ENTERIS BIOPHARMA, INC. 2005-12-22 — — US claimed
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR BRISTOL MYERS SQUIBB CO (US) 2017-12-14 — — US disclosed
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR BRISTOL MYERS SQUIBB CO (US) 2017-12-14 — — US disclosed
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-11-09 — — US disclosed
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-11-09 — — US disclosed
EP-2601188-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-18 — — EP disclosed
US-5498779-A ANTICOAGULANTS AND TREATMENT OF ASTHMA MERRELL PHARMACEUTICALS INC. (US) 1996-03-12 — — US disclosed
US-5391705-A Anticoagulants, treats thrombophlebitis, coronary thrombosis and asthma MERRELL DOW PHARMACEUTICALS INC. (US) 1995-02-21 — — US disclosed
EP-0503203-A1 Novel thrombin inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1992-09-16 — — EP disclosed
EP-0504064-A1 Novel thrombin inhibitors MERRELL PHARMACEUTICALS INC. (US) 1992-09-16 — — EP disclosed
US-4069385-A FROM AN OLEFIN AND AN ORGANIC PEROXIDE WITH COPPER-SCHIFF BASE COMPEX AS CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1978-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR HAVCR2, LIPC, PYGL MAPT 3923/4885ALDH1A1 1107/4885CYP1A2 2057/4885
US-20150125522-A1 ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS VIP, GIPR, FABP2 MAPT 4047/4885ALDH1A1 4678/4885CYP1A2 4155/4885
US-20050282756-A1 Oral delivery of peptide pharmaceutical compositions VIP, GIPR, FABP2 MAPT 4047/4885ALDH1A1 4678/4885CYP1A2 4155/4885
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS MAPT 4065/4885ALDH1A1 1144/4885CYP1A2 2139/4885
US-20120328666-A1 ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS VIP, GIPR, FABP2 MAPT 4047/4885ALDH1A1 4678/4885CYP1A2 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.